Lymphoma clinical trials

300 actively recruiting lymphoma trials in the United States. Hodgkin and non-Hodgkin lymphoma subtypes. Trials explore CAR-T therapy, bispecific antibodies, and relapsed/refractory regimens.

Data from ClinicalTrials.gov · last refreshed 2026-04-20 · Lymphoma stats on SEER

Phase 1

136

Phase 2

Phase 3

Phase 4

Other

Lymphoma by the numbers (U.S.)

80,350

Estimated new cases (2025)

19,390

Estimated deaths (2025)

74.2%

5-year relative survival

Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Top trials by phase + site coverage

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05675410

Locations:

Children's Hospital of Alabama — Birmingham, Alabama
USA Health Strada Patient Care Center — Mobile, Alabama
Providence Alaska Medical Center — Anchorage, Alaska

+ 382 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …

Sponsor: Children's Oncology Group

NCT ID: NCT05602194

Locations:

Children's Hospital of Alabama — Birmingham, Alabama
Providence Alaska Medical Center — Anchorage, Alaska
Kingman Regional Medical Center — Kingman, Arizona

+ 223 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…

Sponsor: Genmab

NCT ID: NCT06191744

Locations:

UCSF Fresno /ID# 264712 — Fresno, California
Scripps Mercy Hospital /ID# 265393 — San Diego, California
Sansum Clinic Research /ID# 261596 — Santa Barbara, California

+ 55 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…

Sponsor: BeiGene

NCT ID: NCT05100862

Locations:

Ucsf Fresno University of California San Francisco Fresno — Fresno, California
Kaiser Permanente Southern California — Irvine, California
Cancer and Blood Specialty Clinic — Los Alamitos, California

+ 46 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…

Sponsor: University of Rochester

NCT ID: NCT05006482

Locations:

Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
Kaiser Permanente-Fremont — Fremont, California
Kaiser Permanente-San Francisco — San Francisco, California

+ 42 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06136559

Locations:

USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona
Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona

+ 38 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06717347

Locations:

Banner MD Anderson Cancer Center ( Site 0165) — Gilbert, Arizona
Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) — Phoenix, Arizona
The University of Arizona Cancer Center - North Campus ( Site 0124) — Tucson, Arizona

+ 33 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC

NCT ID: NCT01804686

Locations:

City of Hope Cancer Center — Duarte, California
University of California San Diego Medical Center — La Jolla, California
University of California Los Angeles — Los Angeles, California

+ 29 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…

Sponsor: BeOne Medicines

NCT ID: NCT06846671

Locations:

St Bernards Medical Center — Jonesboro, Arkansas
UCLA Department of Medicine Hematologyoncology — Los Angeles, California
Pih Health Whittier Hospital — Whittier, California

+ 17 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…

Sponsor: Regeneron Pharmaceuticals

NCT ID: NCT06091254

Locations:

University of Arizona Cancer Center — Tucson, Arizona
David Geffen School of Medicine at UCLA — Los Angeles, California
UC Irvine Health — Orange, California

+ 17 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric a…

Sponsor: Karyopharm Therapeutics Inc

NCT ID: NCT04442022

Locations:

Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
Arizona Oncology Associates — Tucson, Arizona
The Oncology Institute (TOI) Clinical Research — Cerritos, California

+ 16 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.

NCT ID: NCT05254743

Locations:

Pacific Cancer Medical Center, Inc — Anaheim, California
TOI Clinical Research — Cerritos, California
Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California

+ 16 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20

Lymphoma clinical trials

Lymphoma by the numbers (U.S.)

Browse lymphoma trials by state

Top trials by phase + site coverage